|Description||Muraglitazar is a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist(EC50s = 320 and 110 nM in vitro).|
|Synonyms||Pargluva; BMS 298585; BMS-298585; BMS298585; Muraglitazar;N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine;Muraglitazar;N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine;Pargluva|
|Solubility||Soluble in DMSO|
|Storage||Store at -20 °C|
|Application||A peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist.|
|Quality Standard||Enterprise standard|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.|
|Melting Point||123-125 °C|
|Current Developer||Bristol-Myers Squibb|
GSK-3787 is a potent and selective ligand for PPARdelta with good pharmacokinetic properties.
FH535 sodium salt is a dual inhibitor of peroxisome proliferator-activated receptor (PPAR) and Wnt/β-catenin/TCF/LEF signaling. FH535 inhibits recruitment of th...
Troglitazone, PPARγ agonist, is an anti-diabetic thiazolidinedione (TZD) with anti-inflammatory and anti-tumor activity, which was approved for the treatment of...
Seladelpar is a selective peroxisome proliferator-activated receptor -δ receptor agonist. Phase II clinical trials for the treatment of Hyperlipidaemia, Hyperli...
GSK7227 is a novel class of PPARdelta partial agonists. It shows potent partial agonism of the PPARdelta target genes CPT1a and PDK4 in skeletal muscle cells.
Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the b...
NPC 15199 is an amino acid derivative. It is also one of the novel PPARγ ligands that can reduce osteoclasts differentiation through activating PPARγ.
S26948 is a selective PPARγ agonist (EC50 = 8.83 nM). It promotes normal adipocyte differentiation and exhibits a lipid-lowering effect, decreasing the risk of ...